Abbvie Inc. Common Stock (ABBV) 59.55 $ABBV
3 Drugs That Are About to Become Billion-Dollar Blockbusters in 2016
Todd Campbell, The Motley Fool - Motley Fool - 2 hrs 35 mins ago
Source: Bristol-Myers Squibb. It's the hope of every drug developer to create a billion-dollar-per-year blockbuster therapy, but with 90% of drugs failing in clinical trials, few drug companies successfully do it. Bristol-Myers Squibb , Pfizer ...
PFE: 33.82 (-0.95), ABBV: 59.55 (+5.45), BMY: 65.95 (-1.36)
Gilead Sciences Is Shrugging Off Its Competitors
Todd Campbell, The Motley Fool - Motley Fool - Sat Oct 31, 6:20AM CDT
Image source: Gilead Sciences. The fact that Gilead Sciences shares have toppled by 8% since July might have you thinking that competitors have the company on the ropes, but Gilead Sciences' third-quarter results show investors that simply isn't...
GILD: 108.13 (-1.08), MRK: 54.66 (-0.21), ABBV: 59.55 (+5.45)
AbbVie (ABBV) Earnings Report: Q3 2015 Conference Call Transcript
at The Street - Fri Oct 30, 4:41PM CDT
The following AbbVie (ABBV) conference call took place on October 30, 2015, 09:00 AM ET. This is a transcript of that earnings call:
ABBV: 59.55 (+5.45)
Stocks Fall Back Into Red as Financials Lag
at The Street - Fri Oct 30, 1:55PM CDT
Stocks fall back into the red Friday afternoon as a lag in financial stocks overshadows a push higher by the energy sector.
BUD: 119.33 (+1.59), VRX: 93.77 (-17.73), C: 53.17 (-0.49), FNFG: 10.35 (-0.03), XOM: 82.74 (+0.51), BAC: 16.78 (-0.31), WFC: 54.14 (-0.95), KEY: 12.42 (-0.96), SBUX: 62.57 (+0.07), FSLR: 57.07 (+6.08), RDS.A: 52.46 (-0.10), JPM: 64.25 (-0.96), LNKD: 240.87 (+23.87), SCTY: 29.65 (-8.42), CVS: 98.78 (-5.02), BP: 35.70 (-0.01), ABBV: 59.55 (+5.45), XLF: 24.08 (-0.35), CVX: 90.88 (+0.99), PTR: 78.63 (+1.17), XLE: 68.03 (+0.44), STO: 16.16 (+0.19), CL: 66.35 (-2.88)
Why AbbVie Inc. Shares Are Surging 10% Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Fri Oct 30, 1:13PM CDT
Source: AbbVie What: After reporting third quarter financial results that outpaced estimates and issuing long-term financial guidance that stretches out until 2020, shares in AbbVie (NYSE: ABBV) jumped by 10% earlier today. So what: AbbVie...
JNJ: 101.03 (-0.34), ABBV: 59.55 (+5.45)
4 Big Stocks on Traders' Radars: Must-See Charts
at The Street - Fri Oct 30, 11:51AM CDT
These stocks are trading on big volume today. Here's how to trade them from here.
SWKS: 77.24 (+2.61), NYCB: 16.52 (-0.34), AF: 15.96 (-0.57), FNFG: 10.35 (-0.03), MSCC: 36.01 (-0.77), PMCS: 11.92 (+0.28), ABBV: 59.55 (+5.45), KEY: 12.42 (-0.96)
Repros Hits 52-Week Low, FDA Delays Enclomiphene Meeting
Zacks Equity Research - Zacks Investment Research - Fri Oct 30, 10:20AM CDT
Repros Therapeutics (RPRX) hits a 52-week low with the FDA cancelling an advisory meeting (Nov 3) to consider the regulatory application for enclomiphene.
ENDP: 59.99 (-0.39), RPRX: 1.71 (-0.37), ABBV: 59.55 (+5.45)
AbbVie (ABBV) Stock Soars, Raises Guidance as Earnings Beat Expectations
at The Street - Fri Oct 30, 9:47AM CDT
AbbVie (ABBV) stock is spiking in mid-morning trading on Friday, after reporting 2015 third quarter financial results ahead of estimates.
ABBV: 59.55 (+5.45)
Stocks Are Mixed as Chicago Business Activity Improves
at The Street - Fri Oct 30, 9:35AM CDT
Stocks turn mixed by mid-morning after business activity in Chicago rebounds and consumer sentiment improves.
BUD: 119.33 (+1.59), VRX: 93.77 (-17.73), WU: 19.25 (+0.24), XOM: 82.74 (+0.51), SBUX: 62.57 (+0.07), ESRX: 86.38 (-0.77), FSLR: 57.07 (+6.08), LNKD: 240.87 (+23.87), SCTY: 29.65 (-8.42), CVS: 98.78 (-5.02), ABBV: 59.55 (+5.45), CVX: 90.88 (+0.99), CL: 66.35 (-2.88)
AbbVie Tops on 3Q Earnings & Revenues, Ups 2015 View
Arpita Dutt - Zacks Investment Research - Fri Oct 30, 9:10AM CDT
It was a "beat and raise" quarter for AbbVie (ABBV), which also provided its outlook for 2016.
PFE: 33.82 (-0.95), ABBV: 59.55 (+5.45), LLY: 81.57 (-0.43)
AbbVie Beats Q3 Views, Offers Bullish 2020 Guidance
at Investor's Business Daily - Fri Oct 30, 9:00AM CDT
Big pharma AbbVie (ABBV) beat analysts' Q3 estimates and issued five-year guidance that was above expectations Friday morning, sending the stock up sharply in early trading. AbbVie's adjusted earnings rose 27% over the year-earlier quarter to $1.13 a...
JNJ: 101.03 (-0.34), PFE: 33.82 (-0.95), AMGN: 158.18 (-2.40), ABBV: 59.55 (+5.45), NVS: 90.43 (-0.53)
Stock Futures Rise in Final Day of Best Month in 4 Years
at The Street - Fri Oct 30, 7:41AM CDT
Stock futures rise on Friday, on track to close out with the best monthly gain in four years.
BUD: 119.33 (+1.59), VRX: 93.77 (-17.73), WU: 19.25 (+0.24), XOM: 82.74 (+0.51), SBUX: 62.57 (+0.07), ESRX: 86.38 (-0.77), LNKD: 240.87 (+23.87), SCTY: 29.65 (-8.42), NUS: 38.21 (+3.35), CVS: 98.78 (-5.02), ABBV: 59.55 (+5.45), CL: 66.35 (-2.88)
AbbVie (ABBV) Beats on 3Q Earnings & Revenues
Zacks Equity Research - Zacks Investment Research - Fri Oct 30, 7:31AM CDT
AbbVie (ABBV) raised its outlook for 2015 along with reporting better-than-expected results.
ABBV: 59.55 (+5.45)
AbbVie Reports Third-Quarter 2015 Financial Results
PR Newswire Europe - Fri Oct 30, 5:55AM CDT
- Reports Third-Quarter Adjusted EPS of $1.13, Up Nearly 27 Percent and Exceeding Previous Guidance Range of $1.04 to $1.06; Reports GAAP EPS of $0.74
ABBV: 59.55 (+5.45)
AbbVie Outlines Long-Term Strategic and Financial Objectives; Company Positioned for Strong Performance
PR Newswire Europe - Fri Oct 30, 5:54AM CDT
- Company Expects to Deliver Double-Digit Adjusted Earnings-Per-Share (EPS) Growth on Average Through 2020
ABBV: 59.55 (+5.45)
Anheuser-Busch InBev Will Pop Open Its Earnings
at The Street - Thu Oct 29, 7:15PM CDT
Oil giants, pharmaceutical companies and more will reveal their third-quarter earnings results Friday, as will the world's largest brewer, Anheuser-Busch InBev -- which is about to get even larger.
BUD: 119.33 (+1.59), PSX: 89.05 (+2.62), CVS: 98.78 (-5.02), XOM: 82.74 (+0.51), ABBV: 59.55 (+5.45), CVX: 90.88 (+0.99)
Will AbbVie (ABBV) Surprise on Earnings Again in Q3?
Arpita Dutt - Zacks Investment Research - Thu Oct 29, 3:31PM CDT
Focus on AbbVie's (ABBV) third quarter call will be on the performance of key drugs - Humira, Viekira Pak and Imbruvica.
JNJ: 101.03 (-0.34), ESRX: 86.38 (-0.77), GILD: 108.13 (-1.08), SRPT: 24.06 (-0.57), ABBV: 59.55 (+5.45)
AbbVie (ABBV) Stock Higher Ahead of Tomorrow's Earnings Release
at The Street - Thu Oct 29, 1:56PM CDT
AbbVie (ABBV) stock is gaining in midday trading on Thursday, ahead of the release of the company's 2015 third quarter financial results before the market open on Friday.
ABBV: 59.55 (+5.45)
3 Drugs That Are About to Become Billion-Dollar Blockbusters in 2016
Todd Campbell, The Motley Fool - Motley Fool - 2 hrs 35 mins ago
Source: Bristol-Myers Squibb. It's the hope of every drug developer to create a billion-dollar-per-year blockbuster therapy, but with 90% of drugs failing in clinical trials, few drug companies successfully do it. Bristol-Myers Squibb , Pfizer ...
PFE: 33.82 (-0.95), ABBV: 59.55 (+5.45), BMY: 65.95 (-1.36)
Gilead Sciences Is Shrugging Off Its Competitors
Todd Campbell, The Motley Fool - Motley Fool - Sat Oct 31, 6:20AM CDT
Image source: Gilead Sciences. The fact that Gilead Sciences shares have toppled by 8% since July might have you thinking that competitors have the company on the ropes, but Gilead Sciences' third-quarter results show investors that simply isn't...
GILD: 108.13 (-1.08), MRK: 54.66 (-0.21), ABBV: 59.55 (+5.45)
AbbVie (ABBV) Earnings Report: Q3 2015 Conference Call Transcript
at The Street - Fri Oct 30, 4:41PM CDT
The following AbbVie (ABBV) conference call took place on October 30, 2015, 09:00 AM ET. This is a transcript of that earnings call:
ABBV: 59.55 (+5.45)
Stocks Fall Back Into Red as Financials Lag
at The Street - Fri Oct 30, 1:55PM CDT
Stocks fall back into the red Friday afternoon as a lag in financial stocks overshadows a push higher by the energy sector.
BUD: 119.33 (+1.59), VRX: 93.77 (-17.73), C: 53.17 (-0.49), FNFG: 10.35 (-0.03), XOM: 82.74 (+0.51), BAC: 16.78 (-0.31), WFC: 54.14 (-0.95), KEY: 12.42 (-0.96), SBUX: 62.57 (+0.07), FSLR: 57.07 (+6.08), RDS.A: 52.46 (-0.10), JPM: 64.25 (-0.96), LNKD: 240.87 (+23.87), SCTY: 29.65 (-8.42), CVS: 98.78 (-5.02), BP: 35.70 (-0.01), ABBV: 59.55 (+5.45), XLF: 24.08 (-0.35), CVX: 90.88 (+0.99), PTR: 78.63 (+1.17), XLE: 68.03 (+0.44), STO: 16.16 (+0.19), CL: 66.35 (-2.88)
Why AbbVie Inc. Shares Are Surging 10% Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Fri Oct 30, 1:13PM CDT
Source: AbbVie What: After reporting third quarter financial results that outpaced estimates and issuing long-term financial guidance that stretches out until 2020, shares in AbbVie (NYSE: ABBV) jumped by 10% earlier today. So what: AbbVie...
JNJ: 101.03 (-0.34), ABBV: 59.55 (+5.45)
4 Big Stocks on Traders' Radars: Must-See Charts
at The Street - Fri Oct 30, 11:51AM CDT
These stocks are trading on big volume today. Here's how to trade them from here.
SWKS: 77.24 (+2.61), NYCB: 16.52 (-0.34), AF: 15.96 (-0.57), FNFG: 10.35 (-0.03), MSCC: 36.01 (-0.77), PMCS: 11.92 (+0.28), ABBV: 59.55 (+5.45), KEY: 12.42 (-0.96)
Repros Hits 52-Week Low, FDA Delays Enclomiphene Meeting
Zacks Equity Research - Zacks Investment Research - Fri Oct 30, 10:20AM CDT
Repros Therapeutics (RPRX) hits a 52-week low with the FDA cancelling an advisory meeting (Nov 3) to consider the regulatory application for enclomiphene.
ENDP: 59.99 (-0.39), RPRX: 1.71 (-0.37), ABBV: 59.55 (+5.45)
AbbVie (ABBV) Stock Soars, Raises Guidance as Earnings Beat Expectations
at The Street - Fri Oct 30, 9:47AM CDT
AbbVie (ABBV) stock is spiking in mid-morning trading on Friday, after reporting 2015 third quarter financial results ahead of estimates.
ABBV: 59.55 (+5.45)
Stocks Are Mixed as Chicago Business Activity Improves
at The Street - Fri Oct 30, 9:35AM CDT
Stocks turn mixed by mid-morning after business activity in Chicago rebounds and consumer sentiment improves.
BUD: 119.33 (+1.59), VRX: 93.77 (-17.73), WU: 19.25 (+0.24), XOM: 82.74 (+0.51), SBUX: 62.57 (+0.07), ESRX: 86.38 (-0.77), FSLR: 57.07 (+6.08), LNKD: 240.87 (+23.87), SCTY: 29.65 (-8.42), CVS: 98.78 (-5.02), ABBV: 59.55 (+5.45), CVX: 90.88 (+0.99), CL: 66.35 (-2.88)
AbbVie Tops on 3Q Earnings & Revenues, Ups 2015 View
Arpita Dutt - Zacks Investment Research - Fri Oct 30, 9:10AM CDT
It was a "beat and raise" quarter for AbbVie (ABBV), which also provided its outlook for 2016.
PFE: 33.82 (-0.95), ABBV: 59.55 (+5.45), LLY: 81.57 (-0.43)
AbbVie Beats Q3 Views, Offers Bullish 2020 Guidance
at Investor's Business Daily - Fri Oct 30, 9:00AM CDT
Big pharma AbbVie (ABBV) beat analysts' Q3 estimates and issued five-year guidance that was above expectations Friday morning, sending the stock up sharply in early trading. AbbVie's adjusted earnings rose 27% over the year-earlier quarter to $1.13 a...
JNJ: 101.03 (-0.34), PFE: 33.82 (-0.95), AMGN: 158.18 (-2.40), ABBV: 59.55 (+5.45), NVS: 90.43 (-0.53)
Stock Futures Rise in Final Day of Best Month in 4 Years
at The Street - Fri Oct 30, 7:41AM CDT
Stock futures rise on Friday, on track to close out with the best monthly gain in four years.
BUD: 119.33 (+1.59), VRX: 93.77 (-17.73), WU: 19.25 (+0.24), XOM: 82.74 (+0.51), SBUX: 62.57 (+0.07), ESRX: 86.38 (-0.77), LNKD: 240.87 (+23.87), SCTY: 29.65 (-8.42), NUS: 38.21 (+3.35), CVS: 98.78 (-5.02), ABBV: 59.55 (+5.45), CL: 66.35 (-2.88)
AbbVie (ABBV) Beats on 3Q Earnings & Revenues
Zacks Equity Research - Zacks Investment Research - Fri Oct 30, 7:31AM CDT
AbbVie (ABBV) raised its outlook for 2015 along with reporting better-than-expected results.
ABBV: 59.55 (+5.45)
AbbVie Reports Third-Quarter 2015 Financial Results
PR Newswire Europe - Fri Oct 30, 5:55AM CDT
- Reports Third-Quarter Adjusted EPS of $1.13, Up Nearly 27 Percent and Exceeding Previous Guidance Range of $1.04 to $1.06; Reports GAAP EPS of $0.74
ABBV: 59.55 (+5.45)
AbbVie Outlines Long-Term Strategic and Financial Objectives; Company Positioned for Strong Performance
PR Newswire Europe - Fri Oct 30, 5:54AM CDT
- Company Expects to Deliver Double-Digit Adjusted Earnings-Per-Share (EPS) Growth on Average Through 2020
ABBV: 59.55 (+5.45)
Anheuser-Busch InBev Will Pop Open Its Earnings
at The Street - Thu Oct 29, 7:15PM CDT
Oil giants, pharmaceutical companies and more will reveal their third-quarter earnings results Friday, as will the world's largest brewer, Anheuser-Busch InBev -- which is about to get even larger.
BUD: 119.33 (+1.59), PSX: 89.05 (+2.62), CVS: 98.78 (-5.02), XOM: 82.74 (+0.51), ABBV: 59.55 (+5.45), CVX: 90.88 (+0.99)
Will AbbVie (ABBV) Surprise on Earnings Again in Q3?
Arpita Dutt - Zacks Investment Research - Thu Oct 29, 3:31PM CDT
Focus on AbbVie's (ABBV) third quarter call will be on the performance of key drugs - Humira, Viekira Pak and Imbruvica.
JNJ: 101.03 (-0.34), ESRX: 86.38 (-0.77), GILD: 108.13 (-1.08), SRPT: 24.06 (-0.57), ABBV: 59.55 (+5.45)
AbbVie (ABBV) Stock Higher Ahead of Tomorrow's Earnings Release
at The Street - Thu Oct 29, 1:56PM CDT
AbbVie (ABBV) stock is gaining in midday trading on Thursday, ahead of the release of the company's 2015 third quarter financial results before the market open on Friday.
ABBV: 59.55 (+5.45)
